Last month, Castle Biosciences Inc., a Friendswood, Texas-based corporation specializing in rare cancer molecular diagnostics, announced that it had acquired an exclusive worldwide license to intellectual property covering a gene expression profiling test for thymoma, which is a rare tumor derived from the epithelial cells of the thymus gland. Castle Biosciences acquired intellectual property rights from Indiana University Research and Technology Corp., a non-profit technology transfer group associated with the university which discovered the gene profile signature that facilitates Castle Biosciences' DecisionDx-Thymoma test.
Castle Biosciences stated that the test has displayed accurate prediction of metastatic risk in patients with thymoma, while also accurately confirming the disease stage at diagnosis. Castle Biosciences continues to work with Indiana University to complete clinical validation and is aiming to have the test clinically available by the end of this quarter. Patrick Loehrer, director of the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis, stated that "[t]he ability to accurately assess metastatic risk based upon the thymoma's molecular signature will enable personalizing therapeutic options and assist in deciding which patients should receive post-operative therapy."
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.